Dosing & Uses
Dosage Forms & Strengths
vaccine
- 0.5mL/vial
Meningococcal Vaccination
Indicated active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in persons aged 2 years or older
ACIP recommendations: Preferred vaccine for adults ≥56 yr who have not received MenACWY conjugate vaccine (Menactra, Menveo) previously and who require a single dose only (eg, travelers)
0.5 mL SC as a single dose
Up-to-date vaccination schedules available at http://www.cdc.gov/vaccines/schedules/hcp/index.html
Dosing Considerations
MenACWY conjugate vaccine (Menactra, Menveo) preferred for outbreak situations and high risk individuals
Administration
Preferably in deltoid region
Dosage Forms & Strengths
vaccine
- 0.5mL/vial
Immunization
Indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in persons aged 2 years or older
Although approved by the FDA for children ≥2 yr, ACIP pediatric vaccination guidelines do not include the polysaccharide vaccine (Menomune)
<2 years: Safety and efficacy not established
0.5 mL SC as a single dose
Up-to-date vaccination schedules available at http://www.cdc.gov/vaccines/schedules/hcp/index.html
Dosing Considerations
MenACWY conjugate vaccine (Menactra, Menveo) preferred for outbreak situations and high risk individuals
Administration
Preferable in deltoid region
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
>10%
Anorexia
Arthralgia
Diarrhea
Fatigue
Headache
Induration
Malaise
Pain
Redness
Swelling
1-10%
Chills
Fever
Rash
Vomiting
Warnings
Contraindications
Hypersensitivity to any component, including dry natural rubber latex (present in vial stopper)
Cautions
A few cases of Guillain Barre syndrome reported following administration, causality unknown
Not indicated for N. meningitidis serogroup B
Patients with bleeding disorder
Immunosuppressed patients
Pregnancy & Lactation
Pregnancy Category: C
Lactation: use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Meningococcal serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein carrier
These products convey active immunity via stimulation of production of endogenously produced antibodies
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
